Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EUCR Eucrates Biomedical Acquisition (EUCR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Eucrates Biomedical Acquisition Stock (NASDAQ:EUCR) 30 days 90 days 365 days Advanced Chart Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get EUCR alerts:Sign Up Key Stats Today's Range$10.02▼$10.0450-Day Range$10.04▼$10.2552-Week Range$9.87▼$10.25Volume12,700 shsAverage Volume2,287 shsMarket Capitalization$42.27 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEucrates Biomedical Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses to identify and acquire a business in the biomedical or healthcare-related industries in North America and Europe. The company was incorporated in 2020 and is based in New York, New York.Read More… Receive EUCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eucrates Biomedical Acquisition and its competitors with MarketBeat's FREE daily newsletter. Email Address EUCR Stock News HeadlinesZymergen nears final chapter with Bankruptcy Court settlementMay 17, 2024 | bizjournals.comPsyence Biomedical Finalizes Strategic Merger AgreementFebruary 1, 2024 | msn.com2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.December 21, 2024 | Darwin (Ad)What's Going On With Emergent Biosolutions Stock?November 28, 2023 | msn.comMineralys Therapeutics, Inc.: Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne KarydasSeptember 15, 2023 | finanznachrichten.de8-K: Eucrates Biomedical Acquisition Corp.February 18, 2023 | marketwatch.comOcean Biomedical stock falls 26%, down 60% since SPAC mergerFebruary 18, 2023 | msn.comOcean Biomedical Debuts on Nasdaq, Shares Trading 11% LowerFebruary 16, 2023 | marketwatch.comSee More Headlines EUCR Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Eucrates Biomedical Acquisition own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eucrates Biomedical Acquisition investors own include Sprott Focus Trust (FUND), Barrick Gold (GOLD), Meta Platforms (META), ETFMG Alternative Harvest ETF (MJX), New Zealand Energy (NZ), Strathcona Resources (SCR) and Shopify (SHOP). Company Calendar Today12/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorUnclassified Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNASDAQ:EUCR CUSIPN/A CIK1822929 WebN/A Phone212-710-5220FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$2.42 million Net MarginsN/A Pretax MarginN/A Return on Equity-62.82% Return on Assets2.95% Debt Debt-to-Equity RatioN/A Current Ratio2.03 Quick Ratio2.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.81 per share Price / Cash Flow12.36 Book Value($1.25) per share Price / Book-8.03Miscellaneous Outstanding Shares4,210,000Free Float3,386,000Market Cap$42.27 million OptionableNot Optionable Beta-0.07 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:EUCR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eucrates Biomedical Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eucrates Biomedical Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
